Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04404283 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial
NCT04404283 · ClinicalTrials.gov record · last posted 2026-07-22

Brentuximab Vedotin Plus Lenalidomide and Rituximab for the Treatment of Relapsed/Refractory DLBCL

Study acronym: ECHELON-3
StatusActive, Not Recruiting
PhasePhase 3
Started2020-08-20
View on ClinicalTrials.gov ↗
from the ClinicalTrials.gov record
Participants in this study will have diffuse large B-cell lymphoma (DLBCL) that has come back or not gotten better with treatment. The trial will study whether brentuximab vedotin plus two drugs works better to treat this type of cancer than the two drugs alone. Participants will be randomly assigned to get either brentuximab vedotin or placebo. The placebo will look like brentuximab vedotin, but has no medicine in it. Since the study is "blinded," participants and their doctors will not know whether a participant gets brentuximab vedotin or placebo. All participants in the study will get rituximab and lenalidomide. These are drugs that can be used to treat DLBCL.

Protocol amendment history 2 changes detected by DataLookout

2026-04-21
Trial sites reduced: 171 → 145 locations
2026-04-21
Primary completion moved earlier: 2026-12-31 → 2026-01-12
Trial Details
NCT Number NCT04404283
Lead Sponsor Seagen, a wholly owned subsidiary of Pfizer
Conditions Diffuse Large B-cell Lymphoma
Enrollment 239 participants
Start Date 2020-08-20
Primary Completion 2026-01-23 (estimated)
Study Completion 2026-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-07-22